Alkermes Missed Consensus Estimates

Alkermes (ALKS) reported earnings of $0.13 per share on revenue of $306.51 million for the first quarter ended March 2025. The consensus earnings estimate was $0.18 per share on revenue of $316.70 million. The company missed consensus estimates by 27.78% while revenue fell 12.52% compared to the same quarter a year ago.

The company said it continues to expect 2025 revenue of $1.34 billion to $1.43 billion. The current consensus revenue estimate is $1.39 billion for the year ending December 31, 2025.

Alkermes PLC is a biotechnology company engaged in developing, manufacturing & commercializing medicines. The Company has a portfolio of commercial drug products & a clinical pipeline of product candidates that address central nervous system disorders.